Validated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy

被引:2
|
作者
Kaman, Kelsey [1 ,4 ]
Dhodapkar, Meera [2 ]
Shabanova, Veronika [2 ]
McCollum, Sarah [2 ]
Factor, Jeffrey [1 ,3 ]
Leeds, Stephanie [2 ]
机构
[1] Connecticut Asthma & Allergy Ctr, Hartford, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] New England Food Allergy Treatment Ctr, Hartford, CT USA
[4] Connecticut Asthma & Allergy Ctr, 836 Farmington Ave 207, Hartford, CT 06119 USA
关键词
QUALITY-OF-LIFE; FOOD ALLERGY; DISPARITIES; MANAGEMENT; SYMPTOMS; CHILDREN; STRESS; IMPACT;
D O I
10.1016/j.anai.2023.01.028
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Although efficacy, safety, and quality of life measures associated with peanut oral immunotherapy (OIT) have been studied, the relationship between peanut OIT and clinical anxiety has not yet been evaluated. The latter is important to help providers and families have an improved shared medical decision discussion around the benefits of initiating OIT.Objective: To investigate the relationship between undergoing OIT and anxiety in patients with peanut allergy.Methods: In this prospective cross-sectional cohort study, using validated and age-appropriate anxiety scales administered with electronic survey questionnaires, we used generalized linear regressions to compare anxiety between patients undergoing OIT and similar patients with peanut allergy but not on OIT (controls).Results: In the younger cohort (<7 years, n = 80), there was generally a low prevalence of diagnosable anxiety across patients on OIT and controls. In the older cohort (>7 years, n = 125), there was a higher prevalence of anx-iety but no clinically meaningful difference between anxiety scores of patients on OIT and controls. In the older cohort, patients with asthma were more likely to have higher mean anxiety scores (P = .04), as were female patients compared with male patients (P = .004). A subanalysis of separation anxiety scores in the older cohort revealed that younger age (7-12 years vs >12 years, P < .001), non-White race (P = .04), and eczema (P = .02) were found to be meaningful predictors of higher scores. A subanalysis of social anxiety on the older cohort pointed toward non-White race as a meaningful predictor of higher scores (P < .02).Conclusion: The clinical implications of these findings suggest that allergists should particularly consider screen-ing children with food allergy for anxiety and anxiety subtypes among patients who are non-White, female, or have asthma.& COPY; 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 50 条
  • [21] Guideline recommends oral Immunotherapy for Peanut Allergy
    不详
    ALLERGO JOURNAL, 2021, 30 (07) : 55 - 55
  • [22] OUTCOMES OF PEANUT ORAL IMMUNOTHERAPY IN AN ALLERGY CLINIC
    Shroba, J.
    Bandelier, C.
    Pandya, A.
    Parashar, S.
    Portnoy, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S43 - S43
  • [23] Oral immunotherapy for peanut allergy: The pro argument
    Chinthrajah, R. Sharon
    Cao, Shu
    Dunham, Theresa
    Sampath, Vanitha
    Chandra, Sharad
    Chen, Meng
    Sindher, Sayantani
    Nadeau, Kari
    WORLD ALLERGY ORGANIZATION JOURNAL, 2020, 13 (08):
  • [24] The evolution of oral immunotherapy for the treatment of peanut allergy
    Allen, K. J.
    O'Hehir, R. E.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2011, 41 (09): : 1172 - 1174
  • [25] Oral immunotherapy in severe peanut allergy in adults
    Heliovaara, E.
    Kukkonen, K.
    Hakulinen, A.
    Helin, T.
    Voutilainen, H.
    Pelkonen, A.
    Makela, M.
    Kauppi, P.
    ALLERGY, 2015, 70 : 180 - 181
  • [26] Oral Immunotherapy In patients With Peanut Allergy And High Risk Of Anaphylactic Reactions
    Blumchen, K.
    Ulbricht, H.
    Staden, U.
    Dobberstein, K.
    Niggemann, B.
    Wahn, U.
    Beyer, K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S179 - S179
  • [27] Advances in the management of peanut allergy (oral immunotherapy and epicutaneous immunotherapy)
    Wang, Julie
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (01) : 5 - 9
  • [28] Oral immunotherapy for peanut allergy induces eosinophilic esophagitis: three pediatric case reports
    Semancik, Eileen
    Sayej, Wael N.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2016, 27 (05) : 539 - 541
  • [29] Peanut oral immunotherapy in a pediatric allergy clinic: Patient factors associated with clinical outcomes
    Guarnieri, Katharine M.
    Slack, Ian F.
    Gadoury-Levesque, Vanessa
    Eapen, Amy A.
    Andorf, Sandra
    Lierl, Michelle B.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (02) : 214 - +
  • [30] Probiotic and peanut oral immunotherapy: a breakthrough for allergy treatment
    Greenhawt, Matthew J.
    LANCET CHILD & ADOLESCENT HEALTH, 2017, 1 (02): : 80 - 81